GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:PLED BTA) » Definitions » Short Interest

Egetis Therapeutics AB (OSTO:PLED BTA) Short Interest


View and export this data going back to . Start your Free Trial

What is Egetis Therapeutics AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Egetis Therapeutics AB's Short Interest

For the Biotechnology subindustry, Egetis Therapeutics AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egetis Therapeutics AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Short Interest falls into.


;
;

Egetis Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:PLED BTA) » Definitions » Short Interest
Comparable Companies
OSTO:XSPRAY OSTO:SANION OSTO:DMYD B OSTO:SYNACT OSTO:IBT B XSAT:HAMLET B OSTO:HNSA OSTO:FLUO OSTO:MAGLE OSTO:GENO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
EGTX:Sweden 0ABW:UK P0F:Germany
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Website
https://www.egetis.com
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines